Rising Addiction Linked To Smoking Fuels Growth In Quit-Smoking Drug Market Is Supporting Development Across The Quit Smoking Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Quit Smoking Drugs Market Compare Between 2026 And 2030?

The quit smoking drugs market size has seen rapid expansion in recent years. It is projected to increase from $44.23 billion in 2025 to $50.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. The growth observed in the past can be attributed to heightened awareness of smoking hazards, an increase in smoking-related diseases, the availability of nicotine replacement therapies, government anti-smoking campaigns, and the expansion of pharmaceutical manufacturing in developing markets.

The quit smoking drugs market size is anticipated to experience rapid growth in the next few years. It is projected to increase to $90.73 billion in 2030, achieving a compound annual growth rate (CAGR) of 15.5%. This growth in the forecast period can be attributed to advancements in digital health solutions, the rising adoption of personalized medicine, the integration of AI in treatment monitoring, the expansion of telemedicine services, and the proliferation of wearable health monitoring devices. Major trends for the forecast period include personalized nicotine replacement therapies, mobile health (mhealth) and smoking cessation apps, telemedicine-driven prescription support, the integration of behavioral therapy with drug therapy, and wearable devices for monitoring cravings.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9247&type=smp

Which Strategic Drivers Are Supporting The Quit Smoking Drugs Market Development?

The rising incidence of smoking addiction is anticipated to drive the expansion of the quit-smoking drug market in the future. Smoking refers to the act of inhaling and exhaling vapors from burning plant materials such as tobacco, marijuana, and hashish. Quit smoking drugs are prescribed medications used to lessen the desire to smoke by suppressing tobacco cravings and managing nicotine withdrawal symptoms, thereby aiding effective smoking cessation. For example, data from November 2025, released by the OECD (Organisation for Economic Co-operation and Development), a France-based intergovernmental international organization, indicated that 14.8% of individuals aged 15 and over smoked daily in 2023. This daily smoking rate was highest in Türkiye, Hungary, and Greece, as well as in accession/partner countries Indonesia, Bulgaria, and China, where at least one in four people smoked daily. Furthermore, in 2023, an average of 18.5% of men smoked daily compared to 11.4% of women. Thus, the increasing prevalence of smoking addiction is a significant factor propelling the growth of the quit-smoking drug market.

What Segment Categories Are Evaluated In The Quit Smoking Drugs Market Study?

The quit smoking drugs market covered in this report is segmented –

1) By Product: Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, Nicotine Sublingual Tablets

2) By Drug: Varenicline (Chantix), Bupropion (Zyban), Other Drugs

3) By Distribution: Drug Store, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Drug Therapy: Bupropion (Zyban), Varenicline (Chantix)

2) By E-Cigarettes: Disposable E-Cigarettes, Rechargeable E-Cigarettes, Pod Systems

3) By Nicotine Inhalers: Prescription Inhalers, Over-The-Counter Inhalers

4) By Nicotine Replacement Therapies (NRT): Nicotine Patches, Nicotine Gum, Nicotine Lozenges

5) By Nicotine Sublingual Tablets: Fast-Acting Sublingual Tablets, Extended-Release Sublingual Tablets

What Trends Are Affecting The Growth Of The Quit Smoking Drugs Market?

Major companies operating in the quit smoking drugs market are focusing on the creation of new formulations and delivery methods, such as generic tablets, to broaden market leadership across regions and secure a competitive advantage. Generic varenicline tablets are non-branded versions of the medication containing varenicline tartrate, which are bioequivalent to the original branded product and used for smoking cessation therapy. For instance, in January 2024, Lupin Limited, an India-based pharmaceutical company, introduced new Varenicline tablets in the United States, available in 0.5 mg and 1 mg strengths. These tablets represent the generic versions of Chantix tablets (0.5 mg and 1 mg) from PF Prism C.V. and are employed to assist in smoking cessation treatment. As a partial agonist of the nicotinic acetylcholine receptor, varenicline functions by stimulating the release of dopamine, which can mitigate withdrawal symptoms and cravings associated with nicotine addiction. This dual mechanism enables it to reduce the pleasurable effects of smoking while concurrently providing some stimulation to minimize withdrawal effects.

Which Companies Are Engaged In The Quit Smoking Drugs Market Environment?

Major companies operating in the quit smoking drugs market are 22nd Century Group, Cipla Limited, Dr. Reddy’s Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, BioCorRx Inc., Ennaid Therapeutics LLC, Fertin Pharma A/S, Hikma Pharmaceuticals PLC, IntelGenx Technologies Corp., Innovus Pharmaceuticals Inc., Gilla Inc., Rusan Pharma Ltd., Novartis AG

Access The Complete Quit Smoking Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

Which Area Represents The Largest Portion Of The Quit Smoking Drugs Market?

North America was the largest region in the quit smoking drugs market in 2025. The regions covered in the quit smoking drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Quit Smoking Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=9247&type=smp

Browse Through More Reports Similar to the Global Quit Smoking Drugs Market 2026, By The Business Research Company

Quit Smoking Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

Nicotine Addiction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/nicotine-addiction-treatment-global-market-report

Nicotine Addiction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/nicotine-addiction-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795